Tagged with GEN

Saudi Arabia Clinical trials provide a pathway to innovation for clinicians and patients in countries like Saudi Arabia and form a key element of the country’s Vision 2030 national plan. As Saudi transitions away from oil towards becoming a knowledge-based economy, it is hoping to attract ever more international pharma companies to…

Turkey Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing in biosimilars, and how the current pricing system is putting the sustainability of the Turkish pharma industry in danger.  …

Singapore Alan Goh of NDR Medical Technology, a pioneer in intelligent navigation and image processing for minimally invasive surgery, introduces the progress of the company to date, how its technology has been received by surgeons, and the growth strategy he has put in place.   We are trying to overcome the…

Turkey Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies interested in Turkey, and the objective of reaching one billion dollars in revenue. In addition, he outlines Abdi’s international ambitions…

Turkey Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success in consumer health has allowed them to overperform the local market with 27 percent growth in 2020. In addition, she…

China The latest news from the Chinese pharmaceutical industry, including recent deals between domestic pharma giant Simcere and German biotech Vivoryon in Alzheimer’s; Innovent’s tie-up with Ascentage; Biogen’s USD 125 million midstage MS drug pact with InnoCare; and Everest Medicines’ partnership with social media giant Tencent.   Sinopharm Tops Ranking of…

Global Cancer is one of the most frightening words in any language but is especially heart-wrenching when it comes to children. João de Bragança, President of Childhood Cancer International (CCI) and Nicole Scobie, President of Zoé4life and CCI European Board Member, share CCI’s aims as the largest parent-led international organisation supporting…

China A historic approval for Fosun-Kite’s CAR-T therapy Yescarta in China looks set to pave the way for further developments in the Chinese cell and gene therapy space, as multinationals look to bring their new therapies to the rapidly expanding China market   Yescarta, originally approved in the US in 2017…

Switzerland Mental health is a global crisis. 25 percent of the world’s population struggle with mental illness; and mental, neurological, and substance use disorders account for 11 percent of the total global disease burden according to data from the Healthy Brains Global Initiative (HBGI). Global mental healthcare costs are expected to…

USA Dan Leonard of the Association for Accessible Medicines (AAM) highlights five key takeaways from the organisation’s remote but dynamic annual conference, and how the US generics and biosimilars industry might evolve post-COVID.   AAM and our member companies have experienced a year like no other, and the lessons of the…

USA With the US FDA’s controversial recent decision to approve Biogen and Eisai’s aducanumab – the first approval for a new Alzheimer’s disease (AD) drug since 2003 – PharmaBoardroom has raided its archives to bring key industry stakeholders’ takes on the significance of this decision and what it might mean for…

Saudi Arabia Amgen’s Middle East and Africa General Manager Mohamed Nasser discusses the company’s approach to the region; the opportunities in the Saudi market, given its improved regulatory environment; and the disadvantages of its reference pricing system. In addition, Nasser explains Amgen’s approach to Saudization and the company’s place within Saudi Arabia’s…